To ensure access to quality and affordable care for cancer patients within their communities.

 

Links:

Membership
Clinical Pathways

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Email Newsletter
 
Upcoming Events

Save-the-date! Tuesday, November 4, 2014! 
The MOASC Oncology Billing Program will be held at the Sheraton Fairplex Conference Center in Pomona.
The schedule is:
7:30am      Registration - Exhibit Hall - Breakfast
8:00am      Program Begins
11:45am    Lunch – Exhibit Hall
3:00pm      Program concludes

For more information and to register, email moasc@moasc.org or call 909-985-9061 ext. 1 OR click here.

Save-the-date!  Friday, November 14, 2014!
The MOASC Oncology Summit will be held at the InterContinental Hotel in Century City.
The schedule is:
5:00pm      Networking Reception - Exhibit Hall
6:30pm      Dinner – Welcome & Introductions
7:00pm      Keynote presentation
                    Physician Hospital Partnerships: What                    they look like, Whether they work
                    and Should you consider one?

Presented by:
                    Lawrence D. Piro, M.D.
                    President & CEO, The Angeles Clinic
                    MOASC Board of Directors
                    Chair, MOASC Executive Committee
8:30pm      Program concludes

For more information and to register, email moasc@moasc.org or call 909-985-9061 ext. 1.
This meeting precedes Research To Practice - Year In Review Program with Dr. Neil Love on
Saturday, November 15, 2014. For more information visit: www.researchtopractice.com

 
 
 
Hot Topics
<

Medical Oncology Association of Southern California  President's Letter

United We Stand

The practice of oncology is changing. The Medicare Modernization Act, Affordable Care Act, and sequestration have strained oncology practices to the breaking point.  Oncologists are retiring without replacements. Practices are going out of business or bankrupted.

Oncologists are now confronted with rapidly changing contracting freedom.  The proposed Anthem/Blue Cross Cancer Care Quality Program Treatment Pathwaysis the most recent fore by an insurer into controlling medical decisions via financial leverage.

Oncologists are fleeing to hospitals, Kaiser Permanente, and universities as a "safe haven."  But, are they really safe?  As those oncologists age, they will find themselves in an increasing "take it or leave it situation."  Who will defend their employment and medical decision rights?

We at the Medical Oncology Association of Southern California (MOASC) want ALL oncologists to know that we will always stand beside you.  MOASC and the Association of Northern California Oncologists (ANCO) have united and initiated the "Renewal Committee" to ask California oncologists, "What does today's oncologist want and need from its association?"  MOASC and ANCO are committed to reformulate themselves to address the needs of all the current and future oncologists.

MOASC also continues its mission as your voice in State and Federal, insurance, and hospital matters.  MOASC and ANCO fought, and won, its efforts to prevent MediCal from collecting years of past drug reimbursement, that MediCal arbitrarily and retroactively deemed "over-payments."  MOASC is challenging the proposed Anthem/Blue Cross Cancer Care Quality Program Treatment Pathways.  MOASC is part of the fight against the trial lawyers' attack on MICRA, Proposition 46. In his concluding act as MOASC President, my predecessor, Robert A. Moss, M.D., rebuts Proposition 45 in the 2014 California General Election Official Voter Information Guide. MOASC perseveres to protect oncologists' ability to provide unfettered patient care, prevent physician assisted suicide, and thwart over-regulation.

In these difficult times, I am asking you to stay united with your brethren through the Medical Oncology Association of Southern California.  Help us stay politically strong.  Help us help you.  Join, or renew your membership in, MOASC.  Get your colleagues to join as well. Together we can shape oncology in the future.  Together we can dictate how we practice.  Only physicians can provide medical care; only we can cut ourselves out of the decision making through apathy and fragmentation.  United we stand; divide we fall.
Thank you,
Warren Fong, M.D.

Wellpoint will begin implementing its Cancer Care Quality Program Treatment Pathways in November 2014. ANCO and MOASC urge members to review the breast, colorectal, and lung cancer treatment pathways at www.cancercarequalityprogram.com. Send your comments to ANCO execdir@anco-online.org and MOASC moasc@moasc.org.  
(http://med.noridianmedicare.com/web/jeb): MLN Connects Provider eNews (National Provider Calls--Transitioning to ICD-10; Electronic Funds Transfer Upgrades to the Internet-based PECOS System; Open Payments: Know the Numbers and Decode the Data; CMS is Accepting Suggestions for Potential PQRS Measures; New FAQs for PQRS; Cutting-edge Colorectal Cancer Screening Now Covered); CMS 1500 Claim Form Instructions Version 02/12--Revised; Noridian Medicare A/B and DME Comprehensive Error Rate Testing Symposium--California; HCPCS Codes for SNF CB--2015 Annual Update; Upcoming Web-based Workshops (Medicare Part B Claim Submission); Quality Improvement Initiatives; eRx Incentive Program Payments--Now Available; and, November Web-based Workshops. For more information, click here.

Noridian/JEMAC has posted the following updates to its website
(http://med.noridianmedicare.com/web/jeb): MLN Connects Provider eNews (National Provider Calls--Transitioning to ICD-10; Electronic Funds Transfer Upgrades to the Internet-based PECOS System; Open Payments: Know the Numbers and Decode the Data; CMS is Accepting Suggestions for Potential PQRS Measures; New FAQs for PQRS; Cutting-edge Colorectal Cancer Screening Now Covered); CMS 1500 Claim Form Instructions Version 02/12--Revised; Noridian Medicare A/B and DME Comprehensive Error Rate Testing Symposium--California; HCPCS Codes for SNF CB--2015 Annual Update; Upcoming Web-based Workshops (Medicare Part B Claim Submission); Quality Improvement Initiatives; eRx Incentive Program Payments--Now Available; and, November Web-based Workshops. For more information, click here.

On October 27, 2014, the Department of Health Care Services (DHCS) notified providers that it has reviewed all Assembly Bill 97 (AB 97) Ten Percent Pharmacy Payment Reduction and State Plan Amendment (SPA) 12-014 Applications received and postmarked by the May 31, 2014 cutoff. This stakeholder update stated on the DHCS Pharmacy Benefits Division's AB 97 provider exemption webpage, applications received and postmarked on or before May 31, 2014 will be given exemption consideration retroactive to June 01, 2011; applications postmarked after May 31, 2014 will be given consideration for exemption effective the first day of the quarter in which they were received.  Providers who submitted an application by May 31, 2014 will be notified of DHCS's determination via first class mail within the next few weeks.   Individual drugs, or therapeutic categories of drugs meeting one or more of the following criteria will be considered for exemption:
1. Drugs for which immediate or rapid negative clinical impact(s) will occur if consistent and ongoing access is impeded (e.g. drugs used to treat cancer, life-threatening infections, end stage renal disease, hemophilia, etc.). For more information, click here.

MedPAC analyzed data on opioid abuse for Medicare Part D enrollees. Both the findings and potential policy implications could affect practicing hematologists who routinely prescribe opioids. read article For more information, click here.

CMS has released a simplified Open Payments tool at www.cms.gov/OpenPayments/Explore-the-Data/Explore-the-Data.html) that is intended to be easier for the public to use and allowing all data on a physician to be found at a single place. For more information, click here.

 
 
MOASC Information

The MOASC Administrator Program was held on October 22nd at the Disneyland Hotel in Anaheim.
The first presentation was “Alignment with a hospital: Should I stay or should I go?” Presented by: Teri U. Guidi, MBA, FAAMA,President & CEO, Oncology Management Consulting Group. The second presentation was “Patient Satisfaction surveys for PQRS & Meaningful Use” Presented by: Thomas P. Jeffrey, President, SullivanLuallin Group The third presentation was Automation developed by Sargas HIPPA compliant cloud applications and Sargas mHealth makes Chronic Care Management (CCM) feasible, scalable and sustainable” Presented by: Gitesh Patel, Chief Executive Officer, Sargas Pharmaceutical Adherence & Compliance (SPAC) International LLC. The fourth presentation was “Targeted Pure Supplements in Oncology-Revenue and Implementation Model”Presented by: Sreenivas Rao, M.D., President, OncoQol. After lunch, Dawn Holcombe, President of DGH Consulting, and Willis Triplett, Pharm D. Corporate Pharmacy Specialist at HQAA, discussed “USP and Other Major Issues for Oncology: Strategy, Awareness, and Options.
This program was sponsored in part by the following: Merck, Genentech, McKesson, Dendreon, OncoQol, MJ Executive Management on behalf of SayAh, Boehringer-Ingelheim and American Regent.
For a copy of the handouts, please send an email to moasc@moasc.org

The MOASC Clinical Staff Program was held on September 19th in Pasadena.
The first presentation was "Oral Adherence” Presented by: Flora Woo, MSN, RN, Senior Clinical Nurse Consultant, Celgene Corporation.  The second presentation was " Compassion Fatigue: Building Resilience in Oncology Nurses” Presented by: Katherine Joyce Janzen RN, MN, ONC(C), Assistant Professor, School of Nursing and Midwifery; Faculty of Health and Community Studies, Mount Royal University, Calgary, Alberta, Canada. The third presentation was The Art of Active Listening” Presented by: Selinza Ann Mitchell, CNSOncology Clinical Nurse Educator.  
This program was sponsored in part by the following: Celgene, Pfizer, McKesson, Millennium, Eisai, Merck, Genentech, OncoQol, American Regent, and Foundation Medicine.  
For a copy of the handouts, please send an email to moasc@moasc.org

Wednesday, September 10, 2014, 12:00pm - 1:00pm PST. 
Due to overwhelming interest and realization of needing to be prepared, MOASC is
providing an encore presentation of, "Medicare Physician Fee Schedule (PFS)
2015 Proposed Rule, the Value Based Modifier and Changes to Physician
Quality Programs." 
Presented byKelly Davies, Healthcare Policy & Advocacy
Director, Southern CA, Strategic Customer Group, Johnson & Johnson Health
Care Systems Inc. For more information on the 2015 proposed rule, click here.
Physicians may lose up to 9% in Medicare revenue come 2017! 
You cannot afford to miss this encore presentation on Wednesday,
September 10, 2014, 12:00pm - 1:00pm PST. 
To RSVP contact Danielle Overman at moasc@moasc.org.

The MOASC LunchTime Series Webinar was held on August 27th.
The first presentation was "Medicare Physician Fee Schedule (PFS) 2015 Proposed Rule, the Value Based Modifier and Changes to
Physician Quality Programs”
Presented by:Kelly Davies, Healthcare Policy & Advocacy Director, Southern CA, Strategic Customer Group,
Johnson & Johnson Health Care Systems Inc. The second presentation was "Eliminating Collection Costs While Reducing Accounts
Receivables by More Than 61%" 
Presented by:Shawn Ecksel, Vice President, Sales and Development, USPAY.  For a copy of the
handouts, please send an email to moasc@moasc.org

If you did not attend last Wednesday's LunchTime Series Teleconference, "California Regulated Medical Waste Management and Proper Waste Segregation," presented by Richard Best, Technical Director, Stericycle, Inc., you can listen to the recording by dialing 1-888-203-1112 and enter the pass code 353441415#This recording will be available for the next 30 days. To view the handouts for the presentation, please email Danielle Overman at moasc@moasc.org.

Rosetta Genomics announced that enrollment has begun for a prospective Registry of U.S. patients whose tumor biopsy samples have been analyzed by a microRNA-based Gene Expression Profiling (GEP) assay.  This study has been initiated because emerging clinical evidence appears to support the clinical value of this type of testing to improve diagnostic certainty of a specific cancer diagnosis. It is intended that this Registry Study will add considerable evidence validating the clinical utility of microRNA-based GEP by evaluating its impact on patient treatment. Your participation in this Registry Study is therefore vital to its success.  Compensation for completing the Actionability survey for each patient, enrolling each patient and for entering follow-up data will be provided.  For more details please visit http://www.rosettagenomics.com/files/dmfile/registry_
announcement_letter.pdf
or contact Janet Bernard, Study Coordinator: Tel 617-532-5709 or emailjbernard@medpanel.com and / or email to E. Robert Wassman, MD: Robert_wa@rosettagenomics.com.

 

Thank you to the following sponsors for assisting MOASC in achieving their mission.

Platinum:
Diamond:
Bayer Healthcare Pharmaceuticals, Cardinal Health Specialty Solutions, Lilly Oncology, Oncology Supply, Teva Oncology
Gold:

Amgen, Astellas Oncology, Novartis
Silver:
AMAG Pharmaceuticals, AstraZeneca, Dendreon, Genentech, Genomic Health, McKesson Specialty Health, Merck Oncology, Millennium, Onyx Pharmaceuticals, Pfizer, Pharmacyclics, Rosetta Genetics, Seattle Genetics, Sanofi Oncology
Other:

BMS, Myriad

 
© 2008 - 2014 Medical Oncology Association of Southern California
P.O. Box 161   •    Upland, CA 91785
Phone: (909) 985-9061   •    Fax: (909) 985-8581   •   email:
moasc@moasc.org

Open Central 

inland empire website design wow webs